

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT: MESSADEK, Jallal	
		FILING DATE:	GROUP:

11050 U.S. PRO  
09/945391  
08/31/01

## U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

FORGOTTEN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
CTO	A	9	7	0	6	7	9	5 ✓	21.08.96	WO			YES	NO
↓	B	6	7	8	1	5	5	4 ✓	23.07.96	EPO				
	C	9	8	1	6	9	0		06.11.96	WO				
	D	9	5	1	5	7	5	0 ✓	10.12.93	WO				
	E	9	7	3	8	6	8	5 ✓	12.04.96	WO				
↓	F	0	3	4	7	8	6	4 ✓	20.06.89	EPO				
CTO	G	0	0	2	5	7	6	4 ✓	30.10.98	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CTO	H	*	Article from Entrez-PubMed web page entitled: SR 121787, a new orally active fibrinogen receptor antagonist.
	I	*	Article from Entrez-PubMed web page entitled: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist.
	J	*	Article from Entrez-PubMed web page entitled: Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
	K	*	Article from Entrez-PubMed web page entitled: SR 121787, Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
	L	*	Article from Entrez-PubMed web page entitled: Role of platelets in thrombosis and hemostasis.
	M	*	Article from Entrez-PubMed web page entitled: Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
	N	*	Article from Entrez-PubMed web page entitled: The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
CTO	O	*	Article from Entrez-PubMed web page entitled: antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Abstract Only!

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927	SERIAL NO. 09/945,391
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT: MESSADEK, Jallal	
		FILING DATE: August 31, 2001	GROUP: 1614

## U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
CTO	P	* HU 210,122 B	9/28/1992	HU			YES	NO
								X

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CTO	Q	✓	XP-002123170 Database Chemabs 'Online!; Chemical Abstracts Service, Columbus, OH ZAPADNYUK, B.I. et al.: "Bile-secretory effect of trimethylglycine in normal and atherosclerotic animals of different ages" retrieved from STN Database accession no. 107:190742 HCA abstract & BYULL. EKSP. BIOL. MED. (1987), 104(7), 30-2
	R	✓	XP002123171 Database Chemabs 'Online!; Chemical Abstracts Service, Columbus, OH PANTELIMONOVA, T.N. et al.: "Effect of trimethylglycine on lipid metabolism in rabbits with experimental atherosclerosis" retrieved from STN Database accession no. 99:99080 HCA abstract & FARMAKOL. TOKSIKOL. (MOSCOW) (1983), 46(4), 83-5
	S	*	XP-000853747 Fazio B Et al: "Treatment of human atherosclerosis with betaine." MINERVA MED, (1961 APR 25) 52 1511-6., the whole document
	T	*	XP-002123167 P.H. List et al.: "HAGERS HANDBUCH DER PHARMAZEUTISCHEN PRAXIS" 1972, SPRINGER-VERLAG, BERLIN HEIDELBERG, NEW YORK, page 431
	U		XP000853853 "Betaine for homocystinuria." MEDICAL LETTER ON DRUGS AND THERAPEUTICS, (1997) 39/993 (12)., the whole document
	V		XP000853897 WILCKEN D E ET AL: "The natural history of vascular disease in homocystinuria and the effects of treatment." JOURNAL OF INHERITED METABOLIC DISEASE, (1997 JUN) 20 (2) 295-300., the whole document
	W		XP-002123168 J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia" 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON "Betaine hydrochloride" page 1679
CTO	X		XP002123169 "the merck index" 1996, MERCK & CO, WHITEHOUSE STATIONS, NJ "Betaine" page 198

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* not in English  
✓ Abstract Only